Rapid Micro Biosystems Q3 revenue beats estimates

Rapid Micro Biosystems

07/11/2025 11:09

Overview

Rapid Micro Biosystems Q3 revenue grows 3% to $7.8 mln, slightly beating expectations

Net loss for Q3 was $11.5 mln, missing analyst expectations

Outlook

Company raises full-year 2025 revenue guidance to at least $33 mln

Company expects meaningful contribution from multi-system order in Q4 2025

Company sees continued growth in 2026 and beyond

Result Drivers

RECURRING REVENUE GROWTH - Recurring revenue increased 32% due to record consumable sales, contributing significantly to overall revenue growth

RECORD CUSTOMER ORDER - Largest multi-system order from a Top 20 global biopharma customer to automate manufacturing network, supporting future growth

GROSS MARGIN IMPROVEMENT - Gross margin improved by 70 basis points to 9% compared to Q3 2024, despite flat product revenue

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Slight Beat*
$7.80 mln
$7.75 mln (4 Analysts)
Q3 EPS
-$0.26
Q3 Net Income
Miss
-$11.50 mln
-$10.60 mln (3 Analysts)
Q3 Operating Expenses
$12.10 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Rapid Micro Biosystems Inc is $8.00, about 65.6% above its November 6 closing price of $2.75

Press Release: ID:nGNX9RPW71

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)